News Article

Ridge Diagnostics, Inc. and Ameritox, Ltd. Enter into Licensing Agreement for Depression Biomarker Blood Test
Date: Apr 05, 2012
Source: BusinessWeek

Featured firm in this article: Ridge Diagnostics Inc of La Jolla, CA

Ridge Diagnostics, Inc. announced it has entered into an exclusive agreement with Ameritox Ltd. for the license rights to its proprietary developmental blood test MDDScore (TM), a multiple biomarker analysis for Major Depressive Disorder (MDD) for primary care and pain physicians. As part of the agreement, Ameritox has agreed to make an undisclosed equity investment in Ridge and commit to a next-stage clinical development program.

The MDDScore test developed by Ridge Diagnostics measures ten biomarker levels associated with factors such as inflammation, development and maintenance of neurons and interaction between brain structures involved with stress response and other key biological functions. Measurements are analyzed to produce an MDDScore which may help physicians determine whether a patient has major depression.